Non-steroid anti-inflammatory and antirheumatic medicine sales in Germany are forecasted to remain steady from 2024 to 2028, with a per capita value of $7.1. In 2023, the per capita value was also $7.1, indicating no significant growth in this market segment.

The lack of variation suggests a stable demand without year-on-year changes over the forecast period. Consequently, the compound annual growth rate (CAGR) over the last five years is 0%, reflecting a static market with no expansion or contraction.

Future trends to watch for:

Potential impact of new medical research on treatment protocols that might shift demand.
Changes in healthcare policies or reimbursement rates affecting sales.
Emerging competition or new product introductions that could influence market dynamics.